Agios

AGIO NASDAQ
49.09
-2.26
-4.40%
Closed 16:10 05/23 EDT
Open
50.55
Prev Close
51.35
High
50.68
Low
48.46
Volume
389.86K
Avg Vol (3M)
511.14K
52 Week High
99.82
52 Week Low
41.63
% Turnover
0.66%
Market Cap
2.88B
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers Agios AGIO stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.
MORE >

Recently

Name
Price
%Change